I think the above commenter is just pointing out how the fundamental conflict between these two things results in significantly lessened incentive for pharmaceutical companies to put money into researching new antibiotics
I extremely know nothing about this field. Would a naive approach would to have a coordinated “crop rotation” type tactic where all hospitals switched to a primary antibiotic every C years/months do anything?
Empirically, many bacteria seem to be able to acquire resistance in a way that doesn't significantly impact their fitness, meaning they can basically get new resistances and keep old ones for almost arbitrarily long, so the crop rotation idea would fail massively.
It has costs. Replication gets more expensive and slower, more error prone. Also bacteria exchanges resistance DNA among itself. Would be a cool vector to give them weekness.